Basilea may receive additional funding from CARB-X for further preclinical and early clinical development, contingent on certain undisclosed project milestones, as per the company. Image Credit: Marian Weyo / Shutterstock.

Switzerland-based Basilea Pharmaceutica has received a $0.9m grant from the global non-profit, Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), to develop a new antibiotic.

The grant will fund the preclinical development of an antibiotic candidate until the candidate’s nomination, which is expected in H2 this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Basilea added that the company may receive additional funding from CARB-X for further preclinical and early clinical development, contingent on certain undisclosed project milestones.

The antibiotic programme that received funding was developed using the Spexis’ outer membrane protein targeting antibiotics (OMPTA) technology, which Basilea acquired in January.

The OMPTA class of antibiotics binds dually to lipopolysaccharide and outer-membrane proteins. These proteins provide structural integrity and a permeability barrier to protect the gram-negative bacterial cell. Therefore, any disruption in the function of these proteins can cause the bacteria to die.

The CARB-X’s funding is provided through the US Biomedical Advanced Research and Development Authority (BARDA)’s antibacterial branch.

Basilea has previously received funds from the US Government to develop its portfolio of antibacterials and antifungals. The company’s recently approved antibiotic Zevtera (ceftobiprole) was developed through subsidised funding from BARDA.

Antimicrobial resistance (AMR) has become a growing issue in recent years, with the World Health Organisation (WHO) declaring it one of the top global public health and development threats. The US bacterial infection market is expected to be worth $4.1bn by 2024, according to GlobalData.

GlobalData is the parent company of Pharmaceutical Technology.

In light of the growing demand, there has been an increased interest in developing new therapies to combat this issue. In September 2023, Novo Holdings acquired Boston-based Paratek Pharmaceuticals to bolster its AMR expertise. Paratek’s portfolio consisted of Nuzyra (omadacycline), a marketed once-a-day oral and intravenous antibiotic indicated for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

Another antibiotic currently in development is Roche’s zosurabalpin. It is classified under a new antibiotic class of drugs called tethered macrocyclic peptides. Zosurabalpin targets the lipopolysaccharide (LPS) transport systems, which is important for maintaining bacterial cell structure among other functions.

Early R&D project coverage on Pharmaceutical Technology is supported by Mimotopes.

Editorial content is independently produced and follows highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.